Articles tagged with Type 1 Diabetes
Teresa Mastracci, a Senior Scientist at IBRI, has received a $750,000 JDRF Career Development Award to investigate polyamine and hypusine biosynthesis in reversing type 1 diabetes. Her research aims to identify new drugs that preserve or regenerate healthy beta cells, slowing or halting disease progression.
Teresa Mastracci, a researcher at the Indiana Biosciences Research Institute, has received a $750,000 JDRF grant to study polyamine and hypusine biosynthesis for reversing the progression of type 1 diabetes. The goal is to identify new drugs that preserve or regenerate healthy beta cells.
A clinical trial has shown that metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells. This could lead to improved treatment options for Type 1 diabetes patients at risk of developing heart disease.
Research published in Nature Microbiology suggests that antibiotic treatment can alter the microbiome and increase the risk of developing type 1 diabetes. The study used NOD mice and found that short pulses of antibiotics increased disease incidence by 53% compared to control mice.
Researchers found that bilirubin supplementation significantly decreased islet cell death after isolation and nutrient deprivation. The study also showed that bilirubin suppressed the release of damage-associated molecular patterns (DAMPs), which are foreign cell-fighting immune cells.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that a combination of three medications—dapagliflozin, liraglutide, and insulin—helped people with Type 1 diabetes improve blood sugar control and lose weight. The therapy also showed impressive improvements in blood glucose management.
A recent study found that breastfeeding for over three months postpartum alters maternal metabolism, producing lower concentrations of branched-chain amino acids and phospholipids. This change in metabolites is linked to reduced insulin resistance and a lower risk of developing type 2 diabetes.
Researchers found that patients with a rare autoimmune disorder produce antibodies that limit immune-related diseases, including type 1 diabetes. These autoantibodies target proteins such as interferons and interleukins, potentially inhibiting the development of type 1 diabetes.
Researchers tracked daily physical activity in 90 pre- to early-teenage children with type 1 diabetes and found improvements in blood vessel structure and reduced risk factors for heart disease. The study highlights the importance of physical activity for children with type 1 diabetes.
Researchers discovered that isoprene, a common natural chemical found in human breath, increases significantly at hypoglycemia levels. This finding may lead to the development of new tests for detecting hypoglycaemia and reducing its risk of life-threatening complications.
A recent study found that children with Juvenile Inflammatory Arthritis (JIA) have a significantly higher prevalence of Type 1 diabetes compared to the general population. The research, which included over 9,000 patients, suggests that understanding this link may lead to new treatments and preventative interventions for both diseases.
The Fr1da study has detected an early stage of type 1 diabetes in 105 out of 26,760 children aged two to five years. The children have not shown signs of metabolic imbalance, suggesting a potential breakthrough in preventive healthcare. Families are being offered comprehensive support and care.
A commentary published in Diabetes Technology & Therapeutics suggests that insulin pump therapy can lead to better blood glucose control and may be beneficial for all patients with type 1 diabetes. The author highlights the importance of pump technology, including sensor-controlled feedback and artificial pancreas systems.
A recent study published in The Journal of Clinical Investigation found that certain bacteria can activate killer T-cells, which destroy insulin-producing cells and lead to type 1 diabetes. This discovery sheds light on the potential external factors contributing to the disease's development.
Scientists at Washington University School of Medicine and Harvard University have produced insulin-secreting cells from stem cells derived from patients with type 1 diabetes. The new cells can produce insulin in response to glucose and may offer a potential cure for the disease.
Researchers found a direct correlation between increased life expectancy and the rise in type 1 diabetes cases globally. The study suggests that advances in medical care have reduced natural selection, allowing the underlying genetics of the disease to be passed from one generation to the next.
A study by Helmholtz Munich researchers found that viral respiratory tract disorders during the first six months of life significantly increase the risk of children developing type 1 diabetes. The infection localization and timing were key factors in determining the increased risk.
A study published in Diabetes Research and Clinical Practice reveals that children with type 1 diabetes are at risk of low vitamin D levels, affecting bone health, glucose metabolism, and immune function. The research emphasizes the importance of vitamin D screening for all children with type 1 diabetes.
The adAPT trial is a clinical study evaluating the effectiveness of metformin in preventing type 1 diabetes. Researchers aim to identify children at high risk and examine the impact of administering metformin on beta cell stress.
Researchers found that islet transplantation prevents severe hypoglycemic events in people who experienced episodes despite expert care. After one year, 88% of participants were free of severe hypoglycemic events and had restored hypoglycemic awareness.
A clinical trial found that islet transplants effectively prevented severe hypoglycemic events and restored awareness in patients with Type 1 diabetes. The study also demonstrated excellent glycemic control, with nearly 88% of subjects remaining free from severe hypoglycemia at one year.
Scientists have found that the RGS1 gene affects the frequency of T follicular helper cells, which are important for B cell production and seem to be crucial for the disease. The study suggests that while inhibiting RGS1 did not prevent autoimmune diabetes, it changes the way cells move within lymph nodes and spleen.
Two new studies found that life expectancy for people with type 1 diabetes has not decreased compared to the general population over the past few decades. The gap in life expectancy remained constant, with an estimated 12-13 years less life expectancy at birth for those with T1D.
Researchers at TSRI isolated a unique Treg cell from a mouse model of type 1 diabetes and discovered it originates in the thymus, giving rise to two functional states: an nTreg with active FoxP3 and a pre-nTreg without. This discovery opens new avenues for developing novel therapies to prevent autoimmune diseases.
A new study suggests that a combined vaccine therapy using live Salmonella is safe and effective in preventing diabetes in mice. The vaccine works by rebalancing the immune system and preventing the attack on insulin-producing cells. Researchers believe this targeted immunotherapy has great potential for treating type 1 diabetes.
Researchers have discovered a new potential therapy that can protect transplanted human pancreatic islets from dying. The study suggests that pretreating cells with a peptide hormone called cholecystokinin (CCK) may enhance the curative potential of islet transplant for Type 1 diabetes.
Research published in Diabetologia found that people with type 1 diabetes have a three-times increased risk of developing epilepsy later in life. Younger age and severe hypoglycemia are also identified as critical risk factors for brain abnormalities and the development of epilepsy.
Researchers aim to spare people with type 1 diabetes from lifelong insulin therapy by developing three-dimensional cellular structures of insulin-producing cells. The EU-funded project plans to work with pharmaceutical industry partners to mass-produce the cells for transplantation.
Scientists have developed novel insulin mimetopes that can induce regulatory T cells to produce tolerance against insulin, halting the development of type 1 diabetes in young mice. In a humanized mouse model, the new vaccine efficiently stimulates regulatory T cells, which can impede the immune system's attack on insulin-producing cells.
A multicentre study found type 1 diabetes associated with higher cancer incidence, especially for cancers of the stomach, liver, pancreas, endometrium, ovary, and kidney. Women with type 1 diabetes had a smaller but still significant increased risk compared to men.
Researchers have developed a novel therapeutic approach using nanomedicines called Navacims that can reprogram white blood cells to become regulatory cells capable of blunting autoimmune responses. The treatment has shown promising results in preclinical models of diabetes, multiple sclerosis, and rheumatoid arthritis.
Children diagnosed with type 1 diabetes before age seven develop a more aggressive form of the disease compared to teenagers. Researchers found that those diagnosed in childhood retain fewer insulin-producing beta cells than previously thought.
Researchers have identified a new drug target that can restore healthier lipid levels in people with type 1 diabetes. By blocking the growth hormone receptor, MIA-602 has been shown to reduce unhealthy lipids and improve vascular function.
Researchers found a link between pre-kallikrein levels and thickened blood vessels in type 1 diabetes patients. Elevated plasma PK levels are an independent risk factor for whole-body diabetic vascular disease, similar to high triglycerides or high blood pressure.
A study of over 99,000 children found that weight increase during the first year of life is associated with a higher risk of developing type 1 diabetes. The average change in weight from birth to 12 months was linked to an increased risk, while length gain showed no association.
A randomized trial found that metformin did not improve glycemic control after 6 months, despite reducing weight gain and insulin doses. The study included 140 adolescents with type 1 diabetes, aged 12-19 years, and was conducted at 26 pediatric endocrinology clinics.
A large-scale analysis of three diabetes registries found that insulin pump use is associated with lower mean HbA1c levels and better blood sugar control in children and adolescents with type 1 diabetes. Pump use was also more common among certain subgroups, such as girls and non-minority ethnic groups.
Researchers at Helmholtz Munich developed a method to predict the probability of developing postpartum diabetes after childbirth, using BMI and genetic predisposition as key factors. The test showed that women with low-risk scores had an 11% risk of developing diabetes within five years.
Researchers at Monash University discovered that regulatory T cells can function even when their receptors bind to MHC in a completely different orientation, challenging established views on the immune system. This finding opens up new avenues for investigating and potentially treating autoimmune diseases like type 1 diabetes.
Researchers discovered that excess IGFBP3 damages colonic stem cells, leading to intestinal lining damage and chronic gastrointestinal symptoms. A biopharmaceutical blocking circulating levels of the protein has shown promising results in reversing colon damage in diabetic mice.
Researchers have created a new investigational drug that traps IGFBP3, preventing gastrointestinal symptoms and restoring the intestine's mucosal lining structure. The drug may hold promise as a potential treatment for diabetic enteropathy, a common complication of type 1 diabetes.
Researchers create insulin-producing cells using adult tissue and transcription factors, offering a potential cure for type 1 diabetes. The cells can be transplanted into diabetic mice and may lead to clinical trials for human patients.
For patients with low pre-test probability of PE, applying PERC rule should guide diagnostic strategy. Imaging and testing can be reserved for those with high pre-test probability or contraindications to CT pulmonary angiography.
A/Prof Shane Grey's team aims to make significant improvements in islet transplantation therapy, making it a clinically realistic option for more individuals with type 1 diabetes. They focus on calming the immune response of patients to islet transplantation, which could lead to treated individuals living drug-free in the long term.
Researchers developed a drug that blocks hyaluronan buildup in pancreatic islets, preventing immune cell infiltration and destruction of insulin-producing cells. The study suggests a potential preventive treatment for type 1 diabetes in humans if initiated before the onset of the disease.
Researchers from Penn and Baylor have precisely quantified the loss of insulin-producing beta cells in dogs with diabetes, revealing a key similarity with human type I diabetes. The study also identifies features unique to canine diabetes, highlighting potential insights into treating human patients.
A study published in the British Medical Journal found that insulin pump users had a substantially lower risk of dying from cardiovascular disease than those using multiple daily injections. The researchers believe more frequent monitoring and training may be key to the therapy's benefits.
A new study by Joslin researchers reveals that alterations in the DNA damage checkpoint pathway machinery and higher levels of miR200 are associated with severe complications in type 1 diabetes. This finding holds promise for early detection and treatment of complications through therapeutic interventions targeting miR200.
Researchers have discovered a potential new treatment for type 1 diabetes using the anti-inflammatory cytokine interleukin-35, which can reverse or cure the disease in mice models. The study also found that IL-35 concentrations are lower in T1D patients than healthy individuals.
Researchers found that type 1 diabetes patients have significantly lower levels of four proteins (IL8, IL-1Ra, MCP-1, and MIP-1β) that help protect against immune attack. These findings suggest a potential protein cocktail that could aid in disease diagnosis and management, as well as new therapeutic strategies.
The T1DAL study found that alefacept treatment preserved beta cell function in 30% of participants with new-onset type 1 diabetes. Alefacept also reduced insulin dose requirements and major hypoglycemic events compared to the placebo group.
People diagnosed with type 1 diabetes at older ages have weaker brain connections in midlife compared to those who were diagnosed earlier, according to a new study. The research found that individuals diagnosed later in childhood had the weakest brain connectivity as they aged.
A new laser sensor can continuously monitor blood glucose levels without penetrating the skin, offering a pain-free alternative to traditional methods. The technology has potential to improve the lives of millions by enabling constant monitoring and self-regulation.
A new study published in the Journal of Nutrition Education and Behavior found that healthier food options are more expensive than standard options. The researchers recruited families with children aged 1-6 years with type 1 diabetes and found that a healthier market basket cost 18% more than the standard basket.
Researchers have created an implantable device that continuously measures blood sugar levels and automatically releases insulin as needed, eliminating the need for constant monitoring and daily injections. The artificial pancreas maintained blood glucose within target range nearly 80% of the time in computer simulations.
Researchers found that pet care can significantly improve monitoring of Type 1 diabetes in adolescents, leading to lower blood glucose levels. The study's senior author instructs families to associate regular pet fish care with diabetes care, resulting in improved hemoglobin A1C levels.
A Montréal research team found that the dual-hormone artificial pancreas provides the most benefits by reducing time spent in nocturnal hypoglycaemia. The study also showed that no participant using the system experienced a nocturnal hypoglycaemia event requiring treatment.
Researchers have developed a novel approach using liposomes to prevent the onset of Type 1 Diabetes in mice, offering a promising candidate for human vaccination. The technique avoids damaging insulin-producing pancreatic cells and induces immunological tolerance, providing a potential solution for this incurable disease.
A five-year phase II clinical trial testing the ability of BCG to clinically improve type 1 diabetes in adults will be conducted at Massachusetts General Hospital. The trial aims to create a lasting therapeutic response and has received $19 million out of $25 million needed for the study.
Researchers gave disposable cameras to 40 adolescents with Type 1 diabetes to capture their experiences. The findings reveal key differences in boys and less-affluent young people, which could shape patient care and education. The study also highlights the impact of food on managing the disease.